Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 contains only boilerplate legal language.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 contains only boilerplate legal language
- No fiscal-year 2026 financial results or operating metrics disclosed in the provided text
- Investors should review the referenced exhibit for substantive earnings information
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $13.5M, flat YoY, while net loss widened to $78.8M from $67.8M
- Cash $598.6M supports planned operations into 2028, excluding full potential AXPAXLI commercialization costs
- AXPAXLI wet AMD NDA targeted for Q4 2026 after FDA alignment, using the 505(b)(2) pathway with potential review acceleration up to 60 days
- SOL-1 data indicated 17.5% Week 36 and 21.1% Week 52 superiority risk differences versus aflibercept 2 mg
- Estimated injection burden reduction up to 72% versus aflibercept, strengthening potential adherence and commercial positioning if approved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.